Literature DB >> 4598017

Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide.

P H Lagrange, G B Mackaness, T E Miller.   

Abstract

Delayed-type hypersensitivity (DTH) appears in mice immunized with less than an optimal immunogenic dose of sheep red blood cells (SRBC), but is blocked progressively as antibody production increases in response to larger doses of SRBC. Treatment with cyclophosphamide (CY) was shown to release T cells from this inhibitory influence of the humoral response, and cause enhancement of DTH. The magnitude of this enhancing effect on T-cell activity was markedly dependent on the time of treatment relative to the time of immunization, and on the time chosen for measuring DTH. The reasons for these pronounced effects of timing are threefold: (a) CY given before antigenic stimulation has a long-lasting effect on antibody formation, but no apparent effect on the precursors of activated T cells. (b) After antigenic stimulation, T cells also become susceptible to CY. (c) The production of a nonspecific participant (monocyte) in the DTH reaction is also suppressed by CY, though the supply of circulating monocytes is not immediately affected by the drug. The differential effect of CY on T and B lymphocytes depends on the differing physiological states of the majority of cells that make up these two populations. The former are resting cells that are insensitive to CY until exposed to specific antigen, while the latter are drawn from a rapidly replicating precursor pool and are susceptible to CY at all times.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4598017      PMCID: PMC2139678          DOI: 10.1084/jem.139.6.1529

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  The effect of cyclophosphamide on the ontogeny of the humoral immune response in chickens.

Authors:  S P Lerman; W P Weidanz
Journal:  J Immunol       Date:  1970-09       Impact factor: 5.422

2.  Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide.

Authors:  J L Turk; D Parker; L W Poulter
Journal:  Immunology       Date:  1972-10       Impact factor: 7.397

3.  Differential effects of cyclophosphamide on the B and T cell compartments of adult mice.

Authors:  G D Stockman; L R Heim; M A South; J J Trentin
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

Review 4.  Symposium on immunosuppressive drugs. Immunosuppressive drugs. I.

Authors:  G W Santos
Journal:  Fed Proc       Date:  1967 May-Jun

Review 5.  Delayed hypersensitivity.

Authors:  J W Uhr
Journal:  Physiol Rev       Date:  1966-07       Impact factor: 37.312

6.  Kinetics of cyclophosphamide damage--sublethal damage repair and cell-cycle-related sensitivity.

Authors:  W D DeWys; N Kight
Journal:  Mod Hosp       Date:  1969-01

7.  The mediator of cellular immunity. IV. Cooperation between lymphocytes and mononuclear phagocytes.

Authors:  D D McGregor; F T Koster
Journal:  Cell Immunol       Date:  1971-08       Impact factor: 4.868

8.  Initiation of antibody responses by different classes of lymphocytes. V. Fundamental changes in the physiological characteristics of virgin thymus-independent ("B") lymphocytes and "B" memory cells.

Authors:  S Strober
Journal:  J Exp Med       Date:  1972-10-01       Impact factor: 14.307

9.  Further studies on B-lymphocyte suppression in delayed hypersensitivity, indicating a possible mechanism for Jones-Mote hypersensitivity.

Authors:  J L Turk; D Parker
Journal:  Immunology       Date:  1973-04       Impact factor: 7.397

10.  The influence of immunologically committed lymphoid cells on macrophage activity in vivo.

Authors:  G B Mackaness
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more
  107 in total

1.  Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID).

Authors:  T J D'Orazio; J Y Niederkorn
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

2.  Modulation of delayed-type hypersensitivity and cellular immunity to microbial vaccines: effects of cyclophosphamide on the immune response to tularemia vaccine.

Authors:  M S Ascher; D Parker; J L Turk
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

3.  Titration and circulation of cells mediating delayed type hypersensitivity in normal and cyclophosphamide treated mice during response to sheep red blood cells.

Authors:  G Marchal; G Milon; B Hurtrel; P H Lagrance
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

4.  Cyclophosphamide intensifies the acquisition of allergic contact dermatitis in mice rendered B-cell deficient by heterologous anti-IgM antisera.

Authors:  H C Maguire; L Faris; W Weidanz
Journal:  Immunology       Date:  1979-06       Impact factor: 7.397

5.  Drug-induced immunological unresponsiveness: selective inhibition of T-cell 'helper function' by cyclophosphamide in mice pretreated with phytohaemagglutinin.

Authors:  G Schwarze
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

6.  Experimental rabies in skunks: effects of immunosuppression induced by cyclophosphamide.

Authors:  K M Charlton; G A Casey; J B Campbell
Journal:  Can J Comp Med       Date:  1984-01

7.  Relationship between delayed hypersensitivity response and acquired cell-mediated immunity in C57BL/6J mice infected with Leishmania donovani.

Authors:  J R Fahey; R Herman
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

8.  Effect of cyclophosphamide on the immune response to Pseudomonas aeruginosa in mice.

Authors:  C L Pierson; A G Johnson; I Feller
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

9.  Effect of cyclophosphamide on delayed hypersensitivity to Staphylococcus aureus in mice.

Authors:  C S Easmon; A A Glynn
Journal:  Immunology       Date:  1977-11       Impact factor: 7.397

10.  Cyclophosphamide pretreatment and protection against malaria.

Authors:  J F Finerty; E P Krehl
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.